Aetna CVS/pharmacy PDP adds Walmart to preferred pharmacy network
HARTFORD, Conn. — Aetna has announced that Walmart and Sam’s Club pharmacies have been added to the preferred pharmacy network of the Aetna CVS/pharmacy Prescription Drug Plan as of Jan. 1.
The Aetna CVS/pharmacy Prescription Drug Plan offers a median $32 monthly plan premium, as well as fixed co-pays for generic medicines. Medicare beneficiaries who sign up for this plan and fill their prescriptions at a Walmart or Sam’s Club pharmacy may realize savings on their out-of-pocket prescription drug costs. By filling prescription drugs at these preferred pharmacies, as compared to a non-preferred network pharmacy, plan members will:
- Pay a $2 co-payment for nearly 800 preferred generic drugs in most states; and
- Pay a $1 co-payment in all states for specialty generic drugs that are commonly used for the treatment of hypertension, high cholesterol and diabetes.
“We are committed to providing excellent quality and value to our Medicare members,” stated Nancy Cocozza, president of Aetna’s Medicare business. “The addition of Walmart and Sam’s Club pharmacies to the preferred pharmacy network for this plan offers members greater affordability when they purchase medicines at one of these popular pharmacy chains.”
The Aetna CVS/pharmacy Prescription Drug Plan is available in 43 states and the District of Columbia. The plan’s preferred pharmacy network comprises 4,200 Walmart, 580 Sam’s Club and 7,500 CVS/pharmacy locations. In addition to the preferred pharmacy network, members also can use any of the 52,700 pharmacies in the Aetna Medicare network.
Mylan hires Adele Gulfo to head global collaboration, strategic operations
PITTSBURGH — Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.
The company announced Wednesday the appointment of Adele Gulf as EVP global collaboration and strategic operations. Before working for Mylan, Gulfo served as regional president of Latin America for Pfizer’s Emerging Markets Business Unit, overseeing more than 4,000 employees in 23 countries and achieving more than $3 billion in sales in Latin America in 2012.
"Adele’s rich and diverse experience in the pharmaceutical industry will bring significant strategic value and leadership to Mylan in numerous areas," Mylan CEO Heather Bresch said. "For instance, we believe Adele’s expertise will support many of our key growth drivers, including our expansion in Latin America, the development and expansion of our global specialty franchise and the development of global commercial strategies to maximize our key upcoming launches of increasingly complex generic products, such as in the biologics and respiratory areas."
Daiichi Sankyo hopes to get FDA nod for anti-clotting drug
PARSIPPANY, N.J. — Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.
Daiichi Sankyo announced the submission of a new drug application for Savaysa (edoxaban). The company also is hoping to get the FDA’s approval for the pill as a treatment for deep vein thrombosis and pulmonary embolism, as well as preventing the recurrence of symptomatic venous thromboembolism.
"The NDA submission in the United States is an important milestone in the development of edoxaban and reflects our long-standing commitment to addressing the needs of patients living with cardiovascular disease, including those living with AF or VTE," said Daiichi Sanko senior executive officer and global head of research and development Glenn Gormley. "If approved, edoxaban may provide a new treatment option for physicians and their patients with these diseases."